| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569672 | GLAXOSMITHKLINE | Compounds |
Oct, 2013
(10 years ago) | |
| US6025389 | GLAXOSMITHKLINE | Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation |
Oct, 2014
(9 years ago) | |
Bactroban is owned by Glaxosmithkline.
Bactroban contains Mupirocin Calcium.
Bactroban has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bactroban are:
- US5569672
- US6025389
Bactroban was authorised for market use on 18 September, 1995.
Bactroban is available in ointment;nasal, cream;topical dosage forms.
Bactroban can be used as treatment of bacterial infections in the nasal passage of adult patients and health care workers with methicillin resistant s. aureus, treatment of secondarily infected traumatic skin lesions due to s. aureus and s. pyogenes.
The generics of Bactroban are possible to be released after 20 October, 2014.
Drugs and Companies using MUPIROCIN CALCIUM ingredient
Market Authorisation Date: 18 September, 1995
Treatment: Treatment of bacterial infections in the nasal passage of adult patients and health care workers with methicillin resistant s. aureus; Treatment of secondarily infected traumatic skin lesions due to s...
Dosage: OINTMENT;NASAL; CREAM;TOPICAL
BACTROBAN family patents
